目次

1. Tumor Infiltrating Lymphocytes (TIL): A Brief Introduction
1.1 Overview
1.2 TIL History and Concept

2. Emergence Of Tumor Infiltrating Lymphocytes Therapy
2.1 Tumor Infiltrating Lymphocytes As Prognostic Biomarkers
2.2 Tumor Infiltrating Lymphocytes Therapy Combinational Approch

3. Tumor Infiltrating Lymphocytes Therapy Approaches By Cancer: Ongoing Clinical Trials and Trends
3.1 Melanoma
3.2 Colorectal Cancer
3.3 Gastrointestinal Cancers
3.4 Gastric Cancer
3.5 Pancreatic Cancer
3.6 Hepatocellular Carcinoma (Liver Cancer)
3.7 Lung Cancers
3.8 Non Small Cell Lung Cancer
3.9 Gynecological Carcinomas
3.10 Ovarian Cancer
3.11 Uterine/Endometrial Cancer
3.12 Cervical Cancer
3.13 Genitourinary Cancers
3.14 Bladder/Urothelial Carcinoma
3.15 Renal Cell Carcinoma (RCC)
3.16 Prostate Cancer
3.17 Head and Neck Cancer
3.18 Breast Cancer
3.19 Blood Cancer
3.20 Brain Tumors

4. Global Tumour Infiltrating Lymphocyte Therapies Clinical Pipeline Overview
4.1 Company
4.2 Country
4.3 By Indication
4.4 Patient Segment
4.5 By Phase

5. Global Tumour Infiltrating Lymphocyte Therapies Clinical Pipeline By Company, Indication and Phase
5.1 Preclinical
5.2 Clinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Preregistration

6. Tumor Infiltrating Lymphocytes Therapy Proprietary Technologies Insight By Companies

7. Tumor Infiltrating Lymphocytes Therapy Market Trends and Development
7.1 Market Collaborations
7.2 Clinical Outlook

8. Global Tumor Infiltrating Lymphocytes Therapy Market Analysis
8.1 Growing Frontier for Tumor Infiltrating Lymphocyte Therapy Market as Personalized Treatment
8.2 Current Market Scenario
8.3 Therapy Cost Analysis

9. Tumor Infiltrating Lymphocytes Therapy Market Dynamics
9.1 Market Drivers
9.2 Market Challenges

10. Tumor Infiltrating Lymphocytes Therapy Future Market Outlook

11. Competitive Landscape
11.1 Adaptimmune
11.2 AgonOx
11.3 Cellular Biomedicine Group
11.4 Cellular Therapeutics
11.5 GRIT Biotechnology
11.6 Hebei Senlang Biotechnology
11.7 ImmuneCyte
11.8 Instil Bio
11.9 Intima Bioscience
11.10 Iovance Biotherapeutics
11.11 Lyell Immunopharma
11.12 National Cancer Institute (USA)
11.13 National Institutes of Health (USA)
11.14 Nurix
11.15 Obsidian Therapeutics
11.16 OriginCell Therapeutics
11.17 RootPath
11.18 Shanghai Gencells Therapeutics
11.19 SQZ Biotech
11.20 Turnstone Biologics

List of Figures & Tables
Figure 1-1: Procedure of Tumor Infiltrating Lymphocytes Therapy
Figure 1-2: Evolution of Tumor Infiltrating Lymphocytes (TIL) Therapy
Figure 2-1: Combinational Approaches In TILs For Different Cancer Indications
Figure 3-1: Benefits of Tumor Infiltrating Lymphocytes (TIL) in Cancer
Figure 3-2: Evaluation Of Tumor Infiltrating Lymphocytes in Solid Tumors
Figure 3-3: Therapies Used in Combination with Tumor Infiltrating Lymphocytes Therapy
Figure 3-4: Tumor Infiltrating Lymphocytes as Adjuvant Therapy of Melanoma
Figure 3-5: Iovance Biotherapeutics - Melanoma - C-144-01 Trial - Study Initiation and Expected Completion Year
Figure 3-6: Karolinska University Hospital - Melanoma - MAT02 Trial - Study Initiation and Expected Completion Year
Figure 3-7: Role of Tumor Infiltrating Lymphocytes in Colorectal Cancer
Figure 3-8: Colorectal Cancer - M.D. Anderson Cancer Center - MDA-TIL Trial - Study Initiation and Expected Completion Year
Figure 3-9: Colorectal Cancer - NCI - TIL Trial - Study Initiation and Expected Completion Year
Figure 3-10: Colorectal Cancer - University of Pittsburgh - TIL Trial - Study Initiation and Expected Completion Year
Figure 3-11: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
Figure 3-12: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
Figure 3-13: Tumor Infiltrating lymphocytes In Management Of Gastrointestinal Cancer
Figure 3-14: TILs Responsible For Microsatellite Instability In Gastric Cancer
Figure 3-15: Gastric Cancer - University of Pittsburgh -TIL Trial - Study Initiation and Expected Completion Year
Figure 3-16: Gastric Cancer - Fujian Medical University - Study Initiation and Expected Completion Year
Figure 3-17: Gastric Cancer - Intima Biosciences - Study Initiation and Expected Completion Year
Figure 3-18: Pancreatic Cancer - Juncell Therapeutics - Study Initiation and Expected Completion Year
Figure 3-19: Pancreatic Cancer - Shanghai Biomed-Union Biotechnology - Study Initiation and Expected Completion Year
Figure 3-20: Infiltrated T-Cells Assisting the Prognosis of Liver Cancer
Figure 3-21: Hepatocellular Carcinoma - Guangdong Zhaotai InVivo Biomedicine - Study Initiation and Expected Completion Year
Figure 3-22: Hepatocellular Carcinoma - Shanghai Juncell Therapeutics - Study Initiation and Expected Completion Year
Figure 3-23: TIL Therapy for Lung Cancer
Figure 3-24: Type of Infiltrated T-Cells in Lung Cancer
Figure 3-25: Lung Cancer - Guangdong Zhaotai InVivo Biomedicine - Study Initiation and Expected Completion Year
Figure 3-26: Role Of Tumor Infiltrating Lymphocytes In Non-Small Cell Lung Cancer
Figure 3-27: Non-Small Cell Lung Cancer - Iovance Biotherapeutics - Lifileucel/LN-145 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-28: Non-Small Cell Lung Cancer -Iovance Biotherapeutics - LN-145 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-29: Non-Small Cell Lung Cancer -Iovance Biotherapeutics - IOV-4001 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-30: Non-Small Cell Lung Cancer - Cellular Biomedicine - C-TIL051 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-31: Non-Small Cell Lung Cancer - Moffitt Cancer and Research Institute - Study Initiation and Expected Completion Year
Figure 3-32: Non-Small Cell Lung Cancer - Origin Cell Therapeutics - Study Initiation and Expected Completion Year
Figure 3-33: Non-Small Cell Lung Cancer - Intima Biosciences - CISH Inactivated TILs - Study Initiation and Expected Completion Year
Figure 3-34: Non-Small Cell Lung Cancer - BlueHorse Therapeutics - LM103 Injection - Study Initiation and Expected Completion Year
Figure 3-35: Non-Small Cell Lung Cancer - Lyell Immunopharma - LYL-845 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-36: Non-Small Cell Lung Cancer - Instil Bio - ITIL-306 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-37: Non-Small Cell Lung Cancer - Micorbio Co Ltd - MS-20 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-38: Non-Small Cell Lung Cancer - NCI -TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-39: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
Figure 3-40: Global - Number of Deaths by Leading Gynecological Cancer, 2020
Figure 3-41: Role of Tumor Infiltrating Lymphocytes in Various Gynecological Cancer
Figure 3-42: Gynecological Cancer - Junshi Therapeutics -TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-43: Gynecological Cancer - Junshi Therapeutics - GC203 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-44: Gynecological Cancer - Junshi Therapeutics - GC201 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-45: TILs Therapy for Ovarian Cancer
Figure 3-46: Tumor Infiltrating Lymphocytes In Prognosis Of Ovarian Cancer
Figure 3-47: Ovarian Cancer - NCI - TIL Trial - Study Initiation and Expected Completion Year
Figure 3-48: Ovarian Cancer - Herlev Hospital - Relatilimab-Nivolumab and TIL Trial - Study Initiation and Expected Completion Year
Figure 3-49: Ovarian Cancer - Iovance Biotherapeutics - LN-145 and Ln-145-S1 TIL Trial - Study Initiation and Expected Completion Year
Figure 3-50: Ovarian Cancer Targeting Tumor Infiltrating Lymphocytes Therapies in Clinical Trials
Figure 3-51: Tumor Infiltrating Lymphocytes In Prognosis Of Endometrial Cancer
Figure 3-52: Endometrial Cancer - Nurix Therapeutics - DeTIL-0255 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-53: TILs With Prognostic Significance In Cervical Cancer
Figure 3-54: Cervical Cancer - Fudan University - C-TIL052A Injection - Study Initiation and Expected Completion Year
Figure 3-55: Cervical Cancer - OriginCell Therapeutics - TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-56: Cervical Cancer - Senlang Biotechnology - SL22P TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-57: Cervical Cancer - Iovance Biotherapeutics - LN145 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-58: Global - Number of Newly Diagnosed Cases of Leading Genitourinary Cancer, 2020
Figure 3-59: Global - Number of Deaths by Leading Genitourinary Cancer, 2020
Figure 3-60: Infiltrated T-cells in Urothelial Cancer
Figure 3-61: Bladder Cancer - Sheba Medical Center - TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-62: Infiltrated T-Cells in Renal Cell Carcinoma
Figure 3-63: Renal Cell Carcinoma - Instill Bio - ITIL-306 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-64: TIL Therapy For Prostate Cancer
Figure 3-65: TILs In Prognosis Of Prostate Cancer
Figure 3-66: Global - Newly Diagnosed Cases and Deaths related to Head and Neck Cancer, 2020
Figure 3-67: TIL Therapy Procedure For Targeting Head and Neck Cancer
Figure 3-68: TILs In Prognosis Of Head and Neck Cancer
Figure 3-69: Head and neck Cancer - LN-145 TIL Therapy - Study Initiation and Estimated Completion Year
Figure 3-70: Head and neck Cancer - TIL Therapy - Study Initiation and Estimated Completion Year
Figure 3-71: Global - Newly Diagnosed Cases and Deaths related to Breast Cancer (Million), 2020
Figure 3-72: Infiltrating T Cells Assisting In Prognosis Of Breast Cancer
Figure 3-73: TIL Therapy Procedure for Breast Cancer
Figure 3-74: Evaluation of TILs for Breast Cancer
Figure 3-75: Breast Cancer - Iovance Biotherapeutics - TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-76: Breast Cancer - SOLTI Breast Cancer Research Group - NUMARZU-001 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-77: Breast Cancer - Juncell Therapeutics- GC 101 TILTherapy - Study Initiation and Expected Completion Year
Figure 3-78: Breast Cancer - The Affiliated Hospital of Qingdao University - HS-IT 101 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-79: Breast Cancer - Turnstone Biologics - TBio-4101 TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-80: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 3-81: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
Figure 3-82: Infiltration of TILs In Leukemia
Figure 3-83: Tumor Infiltrating Lymphocytes Therapy Procedure in Leukemia
Figure 3-84: Type of Beneficial Infiltrating Cells in Leukemia
Figure 3-85: Global - Newly Diagnosed Cases and Deaths related to Brain Cancer, 2020
Figure 3-86: Role of Tumor Infiltrating Lymphocytes Therapy in Brain Tumor
Figure 3-87: Infiltrated T-Cells in Brain Tumor
Figure 3-88: Brain Cancer - Senlang Biotechnology - TIL Therapy - Study Initiation and Expected Completion Year
Figure 3-89: Brain Cancer - Juncell Therapeutics - TIL Therapy - Study Initiation and Expected Completion Year
Figure 4-1: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Company, 2023 till 2028
Figure 4-2: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Country, 2023 till 2028
Figure 4-3: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Indicating, 2023 till 2028
Figure 4-4: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Patient Segment, 2023 till 2028
Figure 4-5: Global - Tumour Infiltrating Lymphocyte Clinical Trials By Phase, 2023 till 2028
Figure 6-1: Instil Bio - Tumor Processing Method Releases and Preserves All Of The TILs From Tumor Samples
Figure 6-2: Instil Bio - ITIL-168 - Manufacturing and Treatment Process
Figure 6-3: Iovance Biotherapeutics - Steps For Gen 2 TIL Proprietary Technology
Figure 6-4: Iovance Biotherapeutics - Streamlined 22-day GMP Manufacturing Process
Figure 6-5: Design Of Nurix DEL Collection
Figure 6-6: Key Features Of DELigase Platform
Figure 6-7: Nurix’s DNA Encoded Library In Drug Development
Figure 6-8: INTASYL Mechanism Of Action
Figure 6-9: PELEUS Three-Step Process
Figure 6-10: Current VELOS Manufacturing Process
Figure 6-11: TILT-123 Viral Construct
Figure 6-12: TILI-123 Mode Of Action
Figure 6-13: Selected TIL Approach
Figure 6-14: Virus Plus TIL Therapy
Figure 6-15: Structure Of A TALEN
Figure 6-16: TALEN Gene Editing
Figure 6-17: Various Gene Editing Mechanisms Enabled By TALEN
Figure 6-18: TALEN Technology Permits High Specific Cleavage
Figure 6-19: CYTODRIVE Platform
Figure 6-20: Novoleucel Steps Involved
Figure 6-21: TiL Manufacturing Process
Figure 8-1: US - Minimum and Maximum Cost of Tumor Infiltrating Lymphocytes Therapy Treatment, October’2020
Figure 8-2: Proleukin - Cost of Single Powder for Injection, Single Day and Full Treatment (US$), October’2020
Figure 8-3: Cyclophosphamide - Cost of various Supplies of Powder for Injection (US$), October’2020
Figure 8-4: Cyclophosphamide - Price of 2.5ml Supply and Price per ml of Intravenous Solution (US$), October’2020
Figure 8-5: Cyclophosphamide - Average Cost of Single Day and Full Treatment (US$), October’2020
Figure 8-6: Fludarabine - Average Cost of Single Day and Full Treatment (US$), October’2020
Figure 9-1: Driving Forces for Tumor Infiltrating Therapy Market
Figure 9-2: Factors Challenging The Market Growth Of TIL Therapy
Figure 10-1: Global - Global Tumor Infiltrating Lymphocytes Therapy Market Forecast (US$ Million), 2023 - 2028
Figure 10-2: Global - Future Drivers for Tumor Infiltrating Lymphocyte Therapy Market
Figure 10-3: Global - Future Regional Powers for Tumor Infiltrating Lymphocyte Therapy Market